Activating the GPR133 receptor with a small molecule can rebuild bone from within, offering a new direction for osteoporosis ...

Domain Therapeutics Appoints Boston-Based Pharma Leader Jean-Marie Cuillerot, M.D., as Chief Medical Officer -- Internationally recognized clinical strategist with proven track record in translating ...

New study shows that targeting an oft-drugged family of cell membrane receptors with biased modulators can expand potential drug targets and reduce side effects.

G protein–coupled receptors (GPCRs) are versatile molecular machines that regulate the majority of physiological responses to chemically diverse hormones and neurotransmitters. Recent breakthroughs in ...

Detailed price information for Structure Therapeutics Inc (GPCR-Q) from The Globe and Mail including charting and trades.

Septerna's GPCR-targeting platform could unlock novel therapies for a $125B market, with SEP-786 as lead asset. Analysts foresee potential from SEP-786 for hypoparathyroidism, with Phase 1 data ...

G protein-coupled receptors (GPCRs) are transmembrane proteins that transduce an extracellular signal—ligand binding—into an intracellular signal—activation of G-protein—which in turn activates ...

It is a characteristic of cell membrane receptors, which is shared by GPCRs along with G-protein associates. The process of receptor oligomerization is assisted by the cell thermodynamics as well as ...

Detailed price information for Structure Therapeutics Inc (GPCR-Q) from The Globe and Mail including charting and trades.

Pfizer is one of several drugmakers working to develop an alternative to injectable weight loss drugs. Still, it’s far behind rivals like Eli Lilly and Novo Nordisk, who already lead the market with ...

We recently published a list of the 11 Most Promising Small-Cap Stocks According to Analysts. In this article, we are going to take a look at where Structure Therapeutics Inc. (NASDAQ:GPCR) stands ...